Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
Autolus Therapeutics plc - American Depositary Shares (AUTL)
Last autolus therapeutics plc - american depositary shares earnings: 11/7 07:06 am
Check Earnings Report
US:NASDAQ Investor Relations:
autolus.com/investor-relations
Company Research
Source: Business Wire
Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Autolus will assess the feasibility of Cellares’ Cell Shuttle platform to complement its commercial manufacturing operations at the Nucleus facility in Stevenage, UK.Autolus commercializes AUCATZYL® (obecabtagene autoleucel; obe-cel), an autologous CD19 CAR T cell therapy approved in the United States, UK, and Europe for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). Obe-cel is also being studied in ongoing clinical trials to potentially expand its use in pediatric r/
Show less
Read more
Impact Snapshot
Event Time:
AUTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUTL alerts
High impacting Autolus Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AUTL
News
- Autolus Therapeutics (AUTL) Valuation Check After Revenue Guidance And AUCATZYL UK And EU Approvals [Yahoo! Finance]Yahoo! Finance
- Autolus Therapeutics (NASDAQ:AUTL) had its price target lowered by analysts at Needham & Company LLC from $11.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 [Yahoo! Finance]Yahoo! Finance
- Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026GlobeNewswire
- Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform [Yahoo! Finance]Yahoo! Finance
AUTL
Earnings
- 11/12/25 - Miss
AUTL
Sec Filings
- 1/12/26 - Form 424B3
- 1/12/26 - Form 8-K
- 12/3/25 - Form SCHEDULE
- AUTL's page on the SEC website